Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Tuesday 15 December, 2009

UCB

UCB signs a new EUR 1.5 billion credit facility





Brussels, Belgium, December 15 2009 - 8:30 (CET). Regulated
information. - UCB SA ("UCB" or the "Company") is pleased to announce
the signing of its new EUR 1.5 billion revolving credit facility.

The purpose of the facility is to refinance the Company's EUR 4
billion banking facility arranged in connection with the 2006
acquisition of Schwarz Pharma, which has since amortised to
EUR 3.3 billion and is due to mature in October 2011.

The new facility has a three year maturity and a one year extension
option.

The margin and other terms and conditions are customary for similar
investment grade loan facilities.

Prior to arranging this new facility, UCB has successfully issued
three bonds with different maturities raising EUR 1.75 billion in
total from debt capital markets. The proceeds from these bonds will
also be used to refinance the existing credit facility.

Detlef Thielgen, Chief Financial Officer of UCB, commented, "We are
very pleased to have successfully completed this new facility. It is
the next step in our strategy to firmly establish UCB as a global
biopharma industry leader. The fact that all banks originally invited
into this transaction have signed up to the agreement, underscores
the confidence which the loan and debt capital markets have shown in
UCB throughout this refinancing process."


For further information

Richard Simpson, Investor Relations, UCB
T+32.2.559.9494, richard.simpson@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com

Nancy Nackaerts, External Communications, UCB
T +32.473.864.414, nancy.nackaerts@ucb.com


About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of 3.6 billion
euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.


For the pdf-version of this press release, please click on the link
below:


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.